The China Oncology Pipeline Is Going Global — And Pfizer Just Fired the Starting Gun
Pfizer's deal with Innovent Biologics joins a pattern of Western pharma betting on Chinese oncology pipelines to fill post-LOE...
No videos found.
Bonito Biosciences and DaltonTx partner on AI-driven CNS oligotherapeutic delivery
Bonito Biosciences and DaltonTx partner to advance CNS oligotherapeutic delivery using AI-driven screening and computational design for blood-brain barrier...
Lilly Acquires Curevo’s Shingles Vaccine for Up to $1.5 Billion
Lilly acquires shingles vaccine candidate amezosvatein for up to $1.5B, targeting tolerability improvements over existing options.
Blackstone Life Sciences Finances Apogee’s Zumilokibart for $1.3B
Blackstone Life Sciences provides $1.3B in royalty financing and debt for Apogee's zumilokibart, signaling confidence in the IL-13 inhibitor's...
Sanofi’s Venglustat Priority Review Is a Rare Disease Pricing License, Not Just a Clinical Win
FDA's 6-month priority review clock for Sanofi's venglustat in type 3 Gaucher disease—affecting fewer than 1,000 Americans—sets up one...
GENFIT Focuses on ACLF Definition Alignment While Collecting Elafibranor Royalties
GENFIT advances ACLF definition alignment efforts at EASL 2026 while collecting elafibranor royalties from Ipsen's Iqirvo franchise.
Scilex to Spin Out Semnur Pharmaceuticals via Stock Dividend
Scilex spins out Semnur Pharmaceuticals via stock dividend, creating an OTC-traded entity for its Phase 3 SEMDEXA candidate.
CordenPharma Acquires AmbioPharm to Expand Peptide Manufacturing
CordenPharma acquires AmbioPharm to expand peptide manufacturing across three continents, adding critical purification and lyophilization capacity.
Lilly Acquires Curevo for Shingles Vaccine Amezosvatein
Lilly acquires Curevo for shingles vaccine amezosvatein, which reduced activity-limiting side effects by over 50% versus Shingrix in Phase...
The $4 Billion AI Drug Discovery Bet Has a Hidden Ceiling No One Is Pricing In
AI drug discovery attracted $4B in 2024 VC funding, but Phase 3 attrition, payer skepticism, and regulatory opacity threaten...